[{"id":"2a09abe0-6495-491d-a75a-5fe8da47ac10","acronym":"","url":"https://clinicaltrials.gov/study/NCT04086485","created_at":"2021-01-18T20:00:12.098Z","updated_at":"2025-02-25T12:27:19.621Z","phase":"Phase 1/2","brief_title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","source_id_and_acronym":"NCT04086485","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["BRCA • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/03/2022","start_date":" 10/03/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-24"},{"id":"2a6d7e4f-c35c-4e6b-8dc6-72106bb36c61","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750954","created_at":"2023-12-06T16:15:46.614Z","updated_at":"2025-02-25T13:53:37.832Z","phase":"Phase 1","brief_title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","source_id_and_acronym":"NCT04750954","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/22/2021","start_date":" 07/22/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2025-02-20"},{"id":"fdfd9de7-291d-41f6-a1e7-37009f68c58e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665739","created_at":"2021-01-19T20:43:36.156Z","updated_at":"2025-02-25T14:15:45.821Z","phase":"Phase 2","brief_title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","source_id_and_acronym":"NCT04665739","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • everolimus • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 02/03/2023","start_date":" 02/03/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"13a8ea63-40e9-404c-b670-688e9b2c8b54","acronym":"LuDO-N","url":"https://clinicaltrials.gov/study/NCT04903899","created_at":"2021-05-27T13:53:06.417Z","updated_at":"2025-02-25T15:26:53.866Z","phase":"Phase 2","brief_title":"177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk Neuroblastoma","source_id_and_acronym":"NCT04903899 - LuDO-N","lead_sponsor":"Jakob Stenman","biomarkers":" SSTR • CD34 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression","tags":["SSTR • CD34 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 05/20/2031","study_completion_date":" 05/20/2031","last_update_posted":"2025-02-11"},{"id":"4be67477-813c-4d4a-afcc-f5d5c110e3d8","acronym":"ReLUTH","url":"https://clinicaltrials.gov/study/NCT04954820","created_at":"2021-07-08T14:52:46.401Z","updated_at":"2025-02-25T16:45:28.459Z","phase":"Phase 2","brief_title":"Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET","source_id_and_acronym":"NCT04954820 - ReLUTH","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 10/01/2031","primary_completion_date":" 10/01/2031","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2025-02-06"},{"id":"05512785-f9fe-439d-9e0c-f165bade4b72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206060","created_at":"2021-01-18T15:48:09.116Z","updated_at":"2025-02-25T16:44:08.576Z","phase":"Phase 2","brief_title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","source_id_and_acronym":"NCT03206060","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1 • VHL • SSTR","pipe":" | ","alterations":" RET mutation • VHL mutation","tags":["NF1 • VHL • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation • VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 10/10/2017","start_date":" 10/10/2017","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-05"},{"id":"449ed9d2-cfb9-4804-ab05-1adc2070268b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06122610","created_at":"2023-11-08T22:13:11.239Z","updated_at":"2025-02-25T16:47:11.811Z","phase":"Phase 1","brief_title":"Using Novel Imaging to More Safely Treat Neuroendocrine Tumors","source_id_and_acronym":"NCT06122610","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-05"},{"id":"11c83591-4e3f-4858-aa5c-0d9de1fd1c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691465","created_at":"2023-01-20T16:00:13.319Z","updated_at":"2025-02-25T16:54:41.696Z","phase":"Phase 2","brief_title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","source_id_and_acronym":"NCT05691465","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • RB1 • SYP • CHGA","pipe":"","alterations":" ","tags":["TP53 • PTEN • RB1 • SYP • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/27/2023","start_date":" 12/27/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-04"},{"id":"08d03f09-1c0e-4f63-9272-84ef1303882d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04529044","created_at":"2021-01-18T21:41:11.607Z","updated_at":"2025-02-25T15:44:08.465Z","phase":"Phase 2","brief_title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","source_id_and_acronym":"NCT04529044","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" PD-L1 • CDK4 • SSTR","pipe":"","alterations":" ","tags":["PD-L1 • CDK4 • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-12-20"},{"id":"037190b9-a29c-4950-8488-50ec828ead4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04609592","created_at":"2021-02-11T16:55:29.685Z","updated_at":"2025-02-25T15:44:13.594Z","phase":"Phase 1","brief_title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","source_id_and_acronym":"NCT04609592","lead_sponsor":"Stanford University","biomarkers":" SSTR","pipe":" | ","alterations":" PGR expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-10-28"},{"id":"0661b272-42c1-4893-b062-503b09cba715","acronym":"NELMAS","url":"https://clinicaltrials.gov/study/NCT05987176","created_at":"2023-08-14T15:10:04.790Z","updated_at":"2025-02-25T15:54:51.896Z","phase":"Phase 2","brief_title":"Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases","source_id_and_acronym":"NCT05987176 - NELMAS","lead_sponsor":"Imperial College London","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 08/02/2024","start_date":" 08/02/2024","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 03/30/2029","study_completion_date":" 03/30/2029","last_update_posted":"2024-08-09"},{"id":"075a5201-e3f8-44b6-8b44-76394d647793","acronym":"ALPHAMEDIX02","url":"https://clinicaltrials.gov/study/NCT05153772","created_at":"2021-12-10T23:53:34.786Z","updated_at":"2025-02-25T13:49:19.721Z","phase":"Phase 2","brief_title":"Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients","source_id_and_acronym":"NCT05153772 - ALPHAMEDIX02","lead_sponsor":"Radiomedix, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AlphaMedix (SAR447873)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-27"},{"id":"8e9016c5-f335-427f-9f26-0ca96ab2e497","acronym":"LANTana","url":"https://clinicaltrials.gov/study/NCT05178693","created_at":"2022-01-05T12:53:41.791Z","updated_at":"2025-02-25T15:54:18.184Z","phase":"Phase 1","brief_title":"Lutathera and ASTX727 in Neuroendocrine Tumours","source_id_and_acronym":"NCT05178693 - LANTana","lead_sponsor":"Imperial College London","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-20"},{"id":"d35bf2f8-c72c-4e41-b03f-2a4b88237830","acronym":"LuPARP","url":"https://clinicaltrials.gov/study/NCT04375267","created_at":"2021-01-18T21:08:12.416Z","updated_at":"2025-02-25T15:43:58.882Z","phase":"Phase 1","brief_title":"177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours","source_id_and_acronym":"NCT04375267 - LuPARP","lead_sponsor":"Vastra Gotaland Region","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/23/2020","start_date":" 04/23/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-11-14"},{"id":"bc4b4fca-c25c-497b-a1cb-b18eb877c1f0","acronym":"ALPHAMEDIX01","url":"https://clinicaltrials.gov/study/NCT03466216","created_at":"2021-01-19T15:42:04.464Z","updated_at":"2025-02-25T13:48:29.399Z","phase":"Phase 1","brief_title":"Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET","source_id_and_acronym":"NCT03466216 - ALPHAMEDIX01","lead_sponsor":"Radiomedix, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AlphaMedix (SAR447873)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/05/2018","start_date":" 02/05/2018","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2021-08-24"},{"id":"7a3e314a-849d-4495-a24b-b953b748f9d0","acronym":"CHARRT","url":"https://clinicaltrials.gov/study/NCT04039516","created_at":"2021-01-18T19:49:02.396Z","updated_at":"2025-02-25T15:43:38.312Z","phase":"Phase 2","brief_title":"Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy","source_id_and_acronym":"NCT04039516 - CHARRT","lead_sponsor":"King's College Hospital NHS Trust","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2020-08-04"}]